PubMed

Narrative review: hepatobiliary disease in type 2 diabetes mellitus.

Tolman KG, Fonseca V, Tan MH, Dalpiaz A.

Ann Intern Med. 2004 Dec 21;141(12):946-56. Review.PMID: 15611492 [PubMed - indexed for MEDLINE]Related articlesFree article

The multifaceted associations of hepatobiliary disease and diabetes.

Bell DS, Allbright E.

Endocr Pract. 2007 May-Jun;13(3):300-12. Review.PMID: 17599864 [PubMed - indexed for MEDLINE]Related articles

Safety and effectiveness of rosiglitazone in type 2 diabetes patients with nonalcoholic Fatty liver disease.

Wang CH, Leung CH, Liu SC, Chung CH.

J Formos Med Assoc. 2006 Sep;105(9):743-52.PMID: 16959622 [PubMed - indexed for MEDLINE]Related articlesFree article

NASH and the risk of cirrhosis and hepatocellular carcinoma in type 2 diabetes.

Bugianesi E, Vanni E, Marchesini G.

Curr Diab Rep. 2007 Jun;7(3):175-80. Review.PMID: 17547834 [PubMed - indexed for MEDLINE]Related articles

Liver disease and diabetes mellitus.

Baig NA, Herrine SK, Rubin R.

Clin Lab Med. 2001 Mar;21(1):193-207. Review.PMID: 11321935 [PubMed - indexed for MEDLINE]Related articles

Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome.

Derosa G, D'Angelo A, Ragonesi PD, Ciccarelli L, Piccinni MN, Pricolo F, Salvadeo SA, Montagna L, Gravina A, Ferrari I, Paniga S, Cicero AF.

J Clin Pharm Ther. 2006 Aug;31(4):375-83.PMID: 16882108 [PubMed - indexed for MEDLINE]Related articles

Is liver disease a threat to patients with metabolic disorders?

Marchesini G, Forlani G, Bugianesi E.

Ann Med. 2005;37(5):333-46. Review.PMID: 16179269 [PubMed - indexed for MEDLINE]Related articles

Liver disease in patients with diabetes mellitus.

Harrison SA.

J Clin Gastroenterol. 2006 Jan;40(1):68-76. Review.PMID: 16340637 [PubMed - indexed for MEDLINE]Related articles

Mechanisms of Disease: hepatic steatosis in type 2 diabetes--pathogenesis and clinical relevance.

Roden M.

Nat Clin Pract Endocrinol Metab. 2006 Jun;2(6):335-48. Review.PMID: 16932311 [PubMed - indexed for MEDLINE]Related articles

A lifetime modelled economic evaluation comparing pioglitazone and rosiglitazone for the treatment of type 2 diabetes mellitus in the UK.

Tilden DP, Mariz S, O'Bryan-Tear G, Bottomley J, Diamantopoulos A.

Pharmacoeconomics. 2007;25(1):39-54. Erratum in: Pharmacoeconomics. 2007;25(3):237. PMID: 17192117 [PubMed - indexed for MEDLINE]Related articles

Effects of 1 year of treatment with pioglitazone or rosiglitazone added to glimepiride on lipoprotein (a) and homocysteine concentrations in patients with type 2 diabetes mellitus and metabolic syndrome: a multicenter, randomized, double-blind, controlled clinical trial.

Derosa G, Cicero AF, D'Angelo A, Gaddi A, Ciccarelli L, Piccinni MN, Salvadeo SA, Pricolo F, Ferrari I, Gravina A, Ragonesi PD.

Clin Ther. 2006 May;28(5):679-88. Erratum in: Clin Ther. 2006 Sep;28(9):1483. PMID: 16861090 [PubMed - indexed for MEDLINE]Related articles

Review article: type 2 diabetes and chronic liver disease in the Verona diabetes study.

Trombetta M, Spiazzi G, Zoppini G, Muggeo M.

Aliment Pharmacol Ther. 2005 Nov;22 Suppl 2:24-7. Review.PMID: 16225467 [PubMed - indexed for MEDLINE]Related articles

Nonalcoholic fatty liver disease and the metabolic syndrome.

Marchesini G, Babini M.

Minerva Cardioangiol. 2006 Apr;54(2):229-39. Review.PMID: 16778754 [PubMed - indexed for MEDLINE]Related articles

[Therapeutic options for nonalcoholic fatty liver disease and steatohepatitis]

Kluwe J, Lohse AW.

Internist (Berl). 2005 Dec;46(12):1324-30. Review. German. PMID: 16247633 [PubMed - indexed for MEDLINE]Related articles

Glycated hemoglobin and liver disease in diabetes mellitus.

Schnedl WJ, Wallner SJ, Piswanger C, Krause R, Lipp RW.

Wien Med Wochenschr. 2005 Sep;155(17-18):411-5. Review.PMID: 16392439 [PubMed - indexed for MEDLINE]Related articles

[Diabetes mellitus and liver diseases]

Kvapil M.

Vnitr Lek. 2004 May;50(5):379-82. Review. Czech. PMID: 15305636 [PubMed - indexed for MEDLINE]Related articles

A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.

Belfort R, Harrison SA, Brown K, Darland C, Finch J, Hardies J, Balas B, Gastaldelli A, Tio F, Pulcini J, Berria R, Ma JZ, Dwivedi S, Havranek R, Fincke C, DeFronzo R, Bannayan GA, Schenker S, Cusi K.

N Engl J Med. 2006 Nov 30;355(22):2297-307.PMID: 17135584 [PubMed - indexed for MEDLINE]Related articlesFree article

Nonalcoholic fatty liver disease: defining a common problem.

Gasbarrini G, Vero V, Miele L, Forgione A, Hernandez AP, Greco AV, Gasbarrini A, Grieco A.

Eur Rev Med Pharmacol Sci. 2005 Sep-Oct;9(5):253-9. Review.PMID: 16231586 [PubMed - indexed for MEDLINE]Related articles

Effects of pioglitazone and metformin on intracellular lipid content in liver and skeletal muscle of individuals with type 2 diabetes mellitus.

Teranishi T, Ohara T, Maeda K, Zenibayashi M, Kouyama K, Hirota Y, Kawamitsu H, Fujii M, Sugimura K, Kasuga M.

Metabolism. 2007 Oct;56(10):1418-24.PMID: 17884455 [PubMed - indexed for MEDLINE]Related articles

The epidemiology of nonalcoholic fatty liver disease in adults.

Clark JM.

J Clin Gastroenterol. 2006 Mar;40 Suppl 1:S5-10. Review.PMID: 16540768 [PubMed - indexed for MEDLINE]Related articles